Form 4: NextCure Sr VP Acquires 8,270 Stock Options

NextCure, Inc. Senior Vice President Sourav Kundu was granted 8,270 employee stock options with an exercise price of $10.85.

Summary

• Sourav Kundu, Senior Vice President of Development & Manufacturing at NextCure, Inc. (NXTC), was granted 8,270 employee stock options.
• The options have an exercise price of $10.85 per share.
• The earliest transaction date for this grant is January 30, 2026.
• One-fourth of the options will vest on January 30, 2027.
• The remaining options will vest in 36 monthly installments, commencing on February 28, 2027.
• The options have an expiration date of January 29, 2036.
• Following this transaction, Sourav Kundu beneficially owns 8,270 derivative securities (employee stock options).

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it represents a routine executive compensation action that aligns management incentives with shareholder interests, without indicating any immediate operational or financial performance changes.

Positives

• The grant of employee stock options to a Senior Vice President aligns management's long-term interests with those of shareholders, incentivizing performance and retention.
• The options have a long expiration date of January 29, 2036, providing a significant window for potential value realization.

Future Outlook

The vesting schedule for the options, extending through monthly installments beginning February 28, 2027, indicates a long-term incentive structure designed to retain the Senior Vice President and align future performance with shareholder value over several years.

Industry Context

StockSavvy.ai notes that the grant of employee stock options is a standard component of executive compensation packages across various industries, particularly in biotechnology, to attract, retain, and motivate key personnel by linking their financial incentives to the company's stock performance.

Comparison to Industry Standards

• StockSavvy.ai notes that the grant of stock options as part of executive compensation is a common practice across the biotechnology and pharmaceutical industries, similar to companies like Amgen or Gilead Sciences.
• The specific vesting schedule, with a one-year cliff followed by monthly installments, is also a widely adopted structure designed to incentivize long-term executive retention and performance alignment.

Related Party Transactions

• Grant of employee stock options to Senior Vice President Sourav Kundu by NextCure, Inc. This is a standard form of executive compensation and a common related-party transaction.

Stakeholder Impact

• Shareholders: The option grant aims to align the interests of a key executive with those of shareholders, potentially leading to improved long-term company performance.
• Employees: This transaction is specific to a senior executive and does not directly impact the broader employee base, though it reflects the company's compensation strategy for leadership.

Next Steps

• Vesting of one-fourth of the options on January 30, 2027.
• Commencement of 36 monthly vesting installments for the remaining options starting February 28, 2027.

Key Dates

Keywords

NextCure, NXTC, Stock Options, Executive Compensation, Insider Transaction, Form 4, Sourav Kundu